CSS
NRXP icon

Cubist Systematic Strategies’s NRX Pharmaceuticals NRXP Stock Holding History

Cubist Systematic Strategies’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,054
Closed -$50K – 4492
2022
Q1 		$50K Buy
2,054
+877
+75% +$28.5K ﹤0.01% 3377
2021
Q4 		$56K Buy
+1,177
New +$84.9K ﹤0.01% 3296

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cubist Systematic Strategies's NRXP Position: Q2 2022 in Review

Cubist Systematic Strategies sold out of NRX Pharmaceuticals (NRXP) in Q2 2022, closing a stake of 2,054 shares — an estimated $50K sold.

Cubist Systematic Strategies first reported a position in NRXP in Q4 2021 and held it in 2 quarters. The position peaked at $56K in Q4 2021. 37 funds tracked by Wall St. Rank hold NRXP as of Q2 2022.

  • Cubist Systematic Strategies reported no remaining NRX Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 2,054 NRX Pharmaceuticals shares in Q2 2022, an estimated $50K.
  • Cubist Systematic Strategies first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Cubist Systematic Strategies's NRX Pharmaceuticals position peaked at $56K in Q4 2021.
  • 37 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2022.

Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.